University of Ottawa Heart Institute

Summary

University of Ottawa Heart Institute is a medical facility located in OTTAWA, Ontario. This center is recognized for care of Coronary Artery Disease, Atrial Fibrillation, Heart Failure, Cardiovascular Disease, Coronary Syndrome and other specialties. University of Ottawa Heart Institute is involved with conducting 247 clinical trials across 219 conditions. There are 24 research doctors associated with this hospital, such as Benjamin Hibbert, MD, Marc Ruel, MD, Girish Nair, MD, and David H Birnie, MD.

Top PIs

Clinical Trials running at University of Ottawa Heart Institute

Atrial Fibrillation

Coronary Artery Disease

Cardiovascular Disease

Heart Failure

Cardiogenic Shock

Ventricular Tachycardia

Mitral Valve Regurgitation

Stroke

Sarcoidosis

Arrhythmia

Watchman

for Atrial Fibrillation

This trial is testing if it's safe and effective to perform two heart procedures at the same time for patients with atrial fibrillation. One procedure fixes a leaky heart valve without surgery, and the other reduces stroke risk by closing a small part of the heart. This combined approach aims to reduce risks associated with multiple surgeries and anesthesia.

Recruiting

1 award

N/A

6 criteria

Left Atrial Appendage Occlusion vs. NOAC

for Atrial Fibrillation

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.

Recruiting

1 award

N/A

8 criteria

Defibrillator Energy Levels

for Atrial Fibrillation

Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)

Recruiting

1 award

N/A

2 criteria